Capricor Therapeutics (CAPR) Other Accumulated Expenses (2012 - 2026)

Capricor Therapeutics' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 1885.45% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 1885.45% YoY), while the FY2025 annual figure was $3.1 million, up 622.1% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $4.0 million, up from $3.1 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $4.0 million in Q1 2026, with the low at $10000.0 in Q4 2023.
• The 5-year median for Other Accumulated Expenses is $145457.5 (2022), against an average of $1.0 million.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses slumped 88.79% in 2023, then surged 26121.55% in 2025.
• Capricor Therapeutics' Other Accumulated Expenses stood at $89234.0 in 2022, then plunged by 88.79% to $10000.0 in 2023, then soared by 4257.12% to $435712.0 in 2024, then surged by 622.1% to $3.1 million in 2025, then climbed by 27.27% to $4.0 million in 2026.
• Business Quant data shows CAPR's Other Accumulated Expenses at $4.0 million in Q1 2026, $3.1 million in Q4 2025, and $2.6 million in Q3 2025.